Ambulatory use of blinatumomab in paediatric patients with relapsed or refractory B-cell acute lymphoblastic leukaemia at a single centre in South Africa
Acute lymphoblastic leukaemia (ALL) is the most common childhood cancer, with B-ALL comprising approximately 85% of all cases. Despite a high cure rate, those with refractory disease and/or relapsed (R/R) B-ALL have an inferior overall survival. Blinatumomab, a novel therapy, is a bispecific cluster...
Guardat en:
| Autors principals: | , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
AOSIS
2026-05-01
|
| Col·lecció: | South African Journal of Oncology |
| Matèries: | |
| Accés en línia: | https://sajo.org.za/index.php/sajo/article/view/365 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|